Article Detail - JE Part B
COVID-19 Novavax Vaccine, Adjuvanted New Codes
The FDA authorized emergency use of the Novavax COVID-19 vaccine, Adjuvanted for the prevention of COVID-19 disease in patients 18 years and older. CMS issued three new CPT codes for the vaccine product (91304) and the administration (0041A, 0042A) effective July 13, 2022.
Beneficiary cost sharing shall not be applied to the new vaccine product code or the new administration codes.
Code 91304 for vaccine product:
- Long descriptor: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use
- Short descriptor: SARSCOV2 VAC 5MCG/0.5ML IM
Code 0041A for vaccine administration, first dose:
- Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; first dose
- Short descriptor: ADM SARSCOV2 5MCG/0.5ML 1ST
Code 0042A for vaccine administration, second dose:
- Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; second dose
- Short descriptor: ADM SARSCOV2 5MCG/0.5ML 2ND
Visit the COVID-19 Vaccine Provider Toolkit for more information, and get the COVID-19 Vaccines and Monoclonal Antibodies most current list of billing codes, payment allowances, and effective dates. Note: You may need to refresh your browser if you recently visited this webpage.
Source: CMS MLN Connects dated July 21, 2022